(17.07.2024) Lucinda Crabtree was previously CFO at MorphoSys AG. As CFO of MorphoSys, Lucy led a finance team across the US and Germany until the closing of the acquisition of the company by Novartis. Read More
(29.04.2024) Chief Executive Officer Dr. Frank Mathias, one year into his role, is successfully leading the transformation of Oxford Biomedica into a global, pure-play, quality and innovation-led cell and gene therapy CDMO Read More
(20.03.2024) Year to date, Oxford Biomedica has experienced consistently strong demand for its CDMO services across all key viral vector types, with its portfolio of client programmes transitioning towards later stage work. Read More
(11.03.2024) Peter Soelkner has more than 30 years’ experience in the global pharmaceutical services industry with significant CDMO expertise. He is currently Managing Director of Vetter Pharma Read More
(05.03.2024) In line with guidance provided at the Interim Results, revenues for the year ended 31 December 2023 are expected to be approximately £90 million. Operating EBITDA loss for Read More
(29.01.2024) The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica's position as a world-leading cell and gene therapy CDMO. This strategic move broadens the Company's international Read More
(23.01.2024) On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar offering Read More
(07.12.2023) Oxford Biomedica has made significant progress in its streamlining of operations to become a pure-play quality and innovation-led global cell and gene therapy CDMO. The Company has concluded Read More
– Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe – The transaction: Provides Oxford Biomedica with multi viral vector CDMO capabilities – to be made available across the Company’s six manufacturing sites in EU, US and UK… Read More
Newly appointed Chief Executive Officer, Dr. Frank Mathias, is leading a transformation to position Oxford Biomedica as a pure-play CDMO; strategic and operational streamlining ongoing Transformation into a pure-play CDMO by 1 January 2024, with £30 million of annualised costs savings Strong execution and delivery of commercial strategy evidenced by… Read More
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation The Proposed Transaction, would: Provide Oxford Biomedica multi viral vector CDMO capabilities across multiple sites in EU, US and UK… Read More
Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVecta™ system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023. The webinar titled… Read More